全文获取类型
收费全文 | 173960篇 |
免费 | 32731篇 |
国内免费 | 2469篇 |
专业分类
耳鼻咽喉 | 5431篇 |
儿科学 | 6066篇 |
妇产科学 | 2825篇 |
基础医学 | 5725篇 |
口腔科学 | 1941篇 |
临床医学 | 29005篇 |
内科学 | 52127篇 |
皮肤病学 | 7914篇 |
神经病学 | 16958篇 |
特种医学 | 7031篇 |
外国民族医学 | 2篇 |
外科学 | 44507篇 |
综合类 | 792篇 |
现状与发展 | 72篇 |
一般理论 | 26篇 |
预防医学 | 9014篇 |
眼科学 | 3955篇 |
药学 | 2476篇 |
中国医学 | 40篇 |
肿瘤学 | 13253篇 |
出版年
2024年 | 692篇 |
2023年 | 4875篇 |
2022年 | 1371篇 |
2021年 | 3467篇 |
2020年 | 6246篇 |
2019年 | 2555篇 |
2018年 | 7787篇 |
2017年 | 7618篇 |
2016年 | 8671篇 |
2015年 | 8787篇 |
2014年 | 16003篇 |
2013年 | 16430篇 |
2012年 | 6740篇 |
2011年 | 6726篇 |
2010年 | 11056篇 |
2009年 | 14846篇 |
2008年 | 6930篇 |
2007年 | 5281篇 |
2006年 | 7753篇 |
2005年 | 5061篇 |
2004年 | 4247篇 |
2003年 | 3154篇 |
2002年 | 3208篇 |
2001年 | 4156篇 |
2000年 | 3327篇 |
1999年 | 3566篇 |
1998年 | 3902篇 |
1997年 | 3678篇 |
1996年 | 3588篇 |
1995年 | 3390篇 |
1994年 | 2112篇 |
1993年 | 1714篇 |
1992年 | 1641篇 |
1991年 | 1629篇 |
1990年 | 1316篇 |
1989年 | 1372篇 |
1988年 | 1239篇 |
1987年 | 1075篇 |
1986年 | 1087篇 |
1985年 | 925篇 |
1984年 | 776篇 |
1983年 | 740篇 |
1982年 | 736篇 |
1981年 | 607篇 |
1980年 | 576篇 |
1979年 | 520篇 |
1978年 | 503篇 |
1977年 | 535篇 |
1975年 | 404篇 |
1972年 | 424篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
11.
12.
Geneticists have, for years, understood the nature of genome‐wide association studies using common genomic variants. Recently, however, focus has shifted to the analysis of rare variants. This presents potential problems for researchers, as rare variants do not always behave in the same way common variants do, sometimes rendering decades of solid intuition moot. In this paper, we present examples of the differences between common and rare variants. We show why one must be significantly more careful about the origin of rare variants, and how failing to do so can lead to highly inflated type I error. We then explain how to best avoid such concerns with careful understanding and study design. Additionally, we demonstrate that a seemingly low error rate in next‐generation sequencing can dramatically impact the false‐positive rate for rare variants. This is due to the fact that rare variants are, by definition, seen infrequently, making it hard to distinguish between errors and real variants. Compounding this problem is the fact that the proportion of errors is likely to get worse, not better, with increasing sample size. One cannot simply scale their way up in order to solve this problem. Understanding these potential pitfalls is a key step in successfully identifying true associations between rare variants and diseases. 相似文献
13.
A mixed‐method study of effects of a therapeutic play intervention for children on parental anxiety and parents' perceptions of the intervention 下载免费PDF全文
14.
15.
16.
17.
18.
Henry Havel Gregory Finch Pamela Strode Marc Wolfgang Stephen Zale Iulian Bobe Hagop Youssoufian Matthew Peterson Maggie Liu 《The AAPS journal》2016,18(6):1373-1378
Advancing nanomedicines from concept to clinic requires integration of new science with traditional pharmaceutical development. The medical and commercial success of nanomedicines is greatly facilitated when those charged with developing nanomedicines are cognizant of the unique opportunities and technical challenges that these products present. These individuals must also be knowledgeable about the processes of clinical and product development, including regulatory considerations, to maximize the odds for successful product registration. This article outlines these topics with a goal to accelerate the combination of academic innovation with collaborative industrial scientists who understand pharmaceutical development and regulatory approval requirements—only together can they realize the full potential of nanomedicines for patients. 相似文献
19.
PNPLA3 gene polymorphism and response to lifestyle modification in patients with nonalcoholic fatty liver disease 下载免费PDF全文
20.
Srdan Verstovsek MD PhD Jean-Jacques Kiladjian MD PhD Alessandro M. Vannucchi MD Ruben A. Mesa MD FACP Peg Squier MD PhD J. E. Hamer-Maansson MSPH Claire Harrison MD 《Cancer》2023,129(11):1681-1690
Background
In a pooled analysis of the phase 3 Controlled Myelofibrosis Study With Oral JAK Inhibitor Treatment I (COMFORT-I) and COMFORT-II clinical trials, adult patients with intermediate-2 or high-risk myelofibrosis who received oral ruxolitinib at randomization or after crossover from placebo or best available therapy (BAT) had improved overall survival (OS).Methods
This post hoc analysis of pooled COMFORT data examined relevant disease outcomes based on the disease duration (≤12 or >12 months from diagnosis) before ruxolitinib initiation.Results
The analysis included 525 patients (ruxolitinib: ≤12 months, n = 84; >12 months, n = 216; placebo/BAT: ≤12 months, n = 66; >12 months, n = 159); the median age was 65.0–70.0 years. Fewer thrombocytopenia and anemia events were observed among patients who initiated ruxolitinib treatment earlier. At Weeks 24 and 48, the spleen volume response (SVR) was higher for patients who initiated ruxolitinib earlier (47.6% vs. 32.9% at Week 24, p = .0610; 44.0% vs. 26.9% at Week 48, p = .0149). In a multivariable analysis of factors associated with spleen volume reduction, a logistic regression model that controlled for confounding factors found that a significantly greater binary reduction was observed among patients with shorter versus longer disease duration (p = .022). At Week 240, OS was significantly improved among patients who initiated ruxolitinib earlier (63% [95% CI, 51%‒73%] vs. 57% [95% CI, 49%‒64%]; hazard ratio, 1.53; 95% CI, 1.01‒2.31; p = .0430). Regardless of disease duration, a longer OS was observed for patients who received ruxolitinib versus those who received placebo/BAT.Conclusions
These findings suggest that earlier ruxolitinib initiation for adult patients with intermediate-2 and high-risk myelofibrosis may improve clinical outcomes, including fewer cytopenia events, durable SVR, and prolonged OS.Plain Language Summary
- Patients with myelofibrosis, a bone marrow cancer, often do not live as long as the general population. These patients may also have an enlarged spleen and difficult symptoms such as fatigue.
- Two large clinical trials showed that patients treated with the drug ruxolitinib lived longer and had improved symptoms compared to those treated with placebo or other standard treatments.
- Here it was examined whether starting treatment with ruxolitinib earlier (i.e., within a year of diagnosis) provided benefits versus delaying treatment.
- Patients who received ruxolitinib within a year of diagnosis lived longer and experienced fewer disease symptoms than those whose treatment was delayed.